| 24.49 2.67 (12.24%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 30.36 |
1-year : | 35.46 |
| Resists | First : | 26 |
Second : | 30.36 |
| Pivot price | 23.02  |
|||
| Supports | First : | 23.28 |
Second : | 21.61 |
| MAs | MA(5) : | 22.47 |
MA(20) : | 23.56 |
| MA(100) : | 20.22 |
MA(250) : | 21.08 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 31.9 |
D(3) : | 14.1 |
| RSI | RSI(14): 58.3 |
|||
| 52-week | High : | 28.9 | Low : | 12.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BCYC ] has closed below upper band by 10.6%. Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.98 - 25.16 | 25.16 - 25.29 |
| Low: | 22.35 - 22.52 | 22.52 - 22.66 |
| Close: | 24.25 - 24.53 | 24.53 - 24.76 |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Thu, 18 Apr 2024
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up to $21.82 - MarketBeat
Thu, 18 Apr 2024
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement - TipRanks.com - TipRanks
Thu, 11 Apr 2024
Has Bicycle Therapeutics PLC Sponsored (BCYC) Outpaced Other Medical Stocks This Year? - Yahoo Movies UK
Thu, 11 Apr 2024
Bicycle Therapeutics (NASDAQ:BCYC) Shares Down 4.3% - MarketBeat
Wed, 10 Apr 2024
Expert Ratings For Bicycle Therapeutics - Bicycle Therapeutics (NASDAQ:BCYC) - Benzinga
Fri, 05 Apr 2024
Bicycle therapeutics CEO sells shares worth over $75k - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.834e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 17.3 % |
| Return on Equity (ttm) | -23.7 % |
| Qtrly Rev. Growth | 2.698e+007 % |
| Gross Profit (p.s.) | 75.73 |
| Sales Per Share | -63.27 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.39 |
| Price to Cash Flow | 2.49 |
| Dividend | 0 |
| Forward Dividend | 2.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|